Drug-Target identification in COVID-19 disease mechanisms using computational systems biology approaches
| dc.contributor.author | Niarakis, Anna | |
| dc.contributor.author | Ostaszewski, Marek | |
| dc.contributor.author | Mazein, Alexander | |
| dc.contributor.author | Kuperstein, Inna | |
| dc.contributor.author | Kutmon, Martina | |
| dc.contributor.author | Gillespie, Marc E. | |
| dc.contributor.author | Funahashi, Akira | |
| dc.contributor.author | Aichem, Michael | |
| dc.contributor.author | Klein, Karsten | |
| dc.contributor.author | Schreiber, Falk | |
| dc.date.accessioned | 2024-01-16T11:33:16Z | |
| dc.date.available | 2024-01-16T11:33:16Z | |
| dc.date.issued | 2024-02-13 | |
| dc.description.abstract | The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing. Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms.Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue-or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors. Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19. The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies. | |
| dc.description.version | published | deu |
| dc.identifier.doi | 10.3389/fimmu.2023.1282859 | |
| dc.identifier.ppn | 1899381287 | |
| dc.identifier.uri | https://kops.uni-konstanz.de/handle/123456789/69067 | |
| dc.language.iso | eng | |
| dc.subject | SARS-CoV-2 | |
| dc.subject | Systems Biology | |
| dc.subject | Disease maps | |
| dc.subject | mechanistic models | |
| dc.subject | dynamic models | |
| dc.subject | Systems Medicine | |
| dc.subject | large-scale community effort | |
| dc.subject.ddc | 004 | |
| dc.title | Drug-Target identification in COVID-19 disease mechanisms using computational systems biology approaches | eng |
| dc.type | JOURNAL_ARTICLE | |
| dspace.entity.type | Publication | |
| kops.citation.bibtex | @article{Niarakis2024-02-13DrugT-69067,
year={2024},
doi={10.3389/fimmu.2023.1282859},
title={Drug-Target identification in COVID-19 disease mechanisms using computational systems biology approaches},
volume={14},
journal={Frontiers in Immunology},
author={Niarakis, Anna and Ostaszewski, Marek and Mazein, Alexander and Kuperstein, Inna and Kutmon, Martina and Gillespie, Marc E. and Funahashi, Akira and Aichem, Michael and Klein, Karsten and Schreiber, Falk},
note={Article Number: 1282859}
} | |
| kops.citation.iso690 | NIARAKIS, Anna, Marek OSTASZEWSKI, Alexander MAZEIN, Inna KUPERSTEIN, Martina KUTMON, Marc E. GILLESPIE, Akira FUNAHASHI, Michael AICHEM, Karsten KLEIN, Falk SCHREIBER, 2024. Drug-Target identification in COVID-19 disease mechanisms using computational systems biology approaches. In: Frontiers in Immunology. Frontiers. 2024, 14, 1282859. eISSN 1664-3224. Verfügbar unter: doi: 10.3389/fimmu.2023.1282859 | deu |
| kops.citation.iso690 | NIARAKIS, Anna, Marek OSTASZEWSKI, Alexander MAZEIN, Inna KUPERSTEIN, Martina KUTMON, Marc E. GILLESPIE, Akira FUNAHASHI, Michael AICHEM, Karsten KLEIN, Falk SCHREIBER, 2024. Drug-Target identification in COVID-19 disease mechanisms using computational systems biology approaches. In: Frontiers in Immunology. Frontiers. 2024, 14, 1282859. eISSN 1664-3224. Available under: doi: 10.3389/fimmu.2023.1282859 | eng |
| kops.citation.rdf | <rdf:RDF
xmlns:dcterms="http://purl.org/dc/terms/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
xmlns:bibo="http://purl.org/ontology/bibo/"
xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
xmlns:foaf="http://xmlns.com/foaf/0.1/"
xmlns:void="http://rdfs.org/ns/void#"
xmlns:xsd="http://www.w3.org/2001/XMLSchema#" >
<rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/69067">
<dc:contributor>Klein, Karsten</dc:contributor>
<dc:contributor>Aichem, Michael</dc:contributor>
<dc:creator>Niarakis, Anna</dc:creator>
<dc:contributor>Gillespie, Marc E.</dc:contributor>
<dc:creator>Ostaszewski, Marek</dc:creator>
<dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2024-01-16T11:33:16Z</dc:date>
<dc:contributor>Kutmon, Martina</dc:contributor>
<dc:creator>Mazein, Alexander</dc:creator>
<dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/69067/1/Niarakis_2-5q540734qht31.pdf"/>
<dc:contributor>Mazein, Alexander</dc:contributor>
<dc:creator>Kuperstein, Inna</dc:creator>
<dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/43615"/>
<dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/36"/>
<dc:creator>Schreiber, Falk</dc:creator>
<dc:creator>Aichem, Michael</dc:creator>
<void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
<dc:contributor>Ostaszewski, Marek</dc:contributor>
<foaf:homepage rdf:resource="http://localhost:8080/"/>
<dc:contributor>Kuperstein, Inna</dc:contributor>
<dc:creator>Kutmon, Martina</dc:creator>
<dc:creator>Funahashi, Akira</dc:creator>
<dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/43615"/>
<dcterms:title>Drug-Target identification in COVID-19 disease mechanisms using computational systems biology approaches</dcterms:title>
<dcterms:abstract>The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing. Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms.Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue-or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors. Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19. The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies.</dcterms:abstract>
<dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/69067/1/Niarakis_2-5q540734qht31.pdf"/>
<bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/69067"/>
<dcterms:issued>2024-02-13</dcterms:issued>
<dc:creator>Klein, Karsten</dc:creator>
<dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2024-01-16T11:33:16Z</dcterms:available>
<dc:contributor>Niarakis, Anna</dc:contributor>
<dc:language>eng</dc:language>
<dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/36"/>
<dc:contributor>Schreiber, Falk</dc:contributor>
<dc:creator>Gillespie, Marc E.</dc:creator>
<dc:contributor>Funahashi, Akira</dc:contributor>
</rdf:Description>
</rdf:RDF> | |
| kops.description.openAccess | openaccessgold | |
| kops.flag.etalAuthor | true | |
| kops.flag.isPeerReviewed | true | |
| kops.flag.knbibliography | true | |
| kops.identifier.nbn | urn:nbn:de:bsz:352-2-5q540734qht31 | |
| kops.sourcefield | Frontiers in Immunology. Frontiers. 2024, <b>14</b>, 1282859. eISSN 1664-3224. Verfügbar unter: doi: 10.3389/fimmu.2023.1282859 | deu |
| kops.sourcefield.plain | Frontiers in Immunology. Frontiers. 2024, 14, 1282859. eISSN 1664-3224. Verfügbar unter: doi: 10.3389/fimmu.2023.1282859 | deu |
| kops.sourcefield.plain | Frontiers in Immunology. Frontiers. 2024, 14, 1282859. eISSN 1664-3224. Available under: doi: 10.3389/fimmu.2023.1282859 | eng |
| relation.isAuthorOfPublication | 549e9182-c528-4817-81d8-00677d09a6a5 | |
| relation.isAuthorOfPublication | 783856d3-db6f-4abb-8969-9efd393896c7 | |
| relation.isAuthorOfPublication | 4a62a6c5-bf37-4efa-a633-4229ff88ed2e | |
| relation.isAuthorOfPublication.latestForDiscovery | 549e9182-c528-4817-81d8-00677d09a6a5 | |
| source.bibliographicInfo.articleNumber | 1282859 | |
| source.bibliographicInfo.volume | 14 | |
| source.identifier.eissn | 1664-3224 | |
| source.periodicalTitle | Frontiers in Immunology | |
| source.publisher | Frontiers |
Dateien
Originalbündel
1 - 1 von 1
Vorschaubild nicht verfügbar
- Name:
- Niarakis_2-5q540734qht31.pdf
- Größe:
- 5.98 MB
- Format:
- Adobe Portable Document Format
